Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Towards Targeting the Urotensinergic System: Overview and Challenges.

Nassour H, Iddir M, Chatenet D.

Trends Pharmacol Sci. 2019 Oct;40(10):725-734. doi: 10.1016/j.tips.2019.08.005. Epub 2019 Sep 6. Review.

PMID:
31500846
2.

The amidated PACAP1-23 fragment is a potent reduced-size neuroprotective agent.

Lamine A, Poujol de Molliens M, Létourneau M, Hébert TE, Vaudry D, Fournier A, Chatenet D.

Biochim Biophys Acta Gen Subj. 2019 Nov;1863(11):129410. doi: 10.1016/j.bbagen.2019.08.003. Epub 2019 Aug 8.

PMID:
31401178
3.

Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor.

Poujol de Molliens M, Jamadagni P, Létourneau M, Devost D, Hébert TE, Patten SA, Fournier A, Chatenet D.

Biochim Biophys Acta Gen Subj. 2019 Nov;1863(11):129398. doi: 10.1016/j.bbagen.2019.07.007. Epub 2019 Jul 12.

PMID:
31306709
4.

Targeting the PAC1 Receptor for Neurological and Metabolic Disorders.

Liao C, de Molliens MP, Schneebeli ST, Brewer M, Song G, Chatenet D, Braas KM, May V, Li J.

Curr Top Med Chem. 2019;19(16):1399-1417. doi: 10.2174/1568026619666190709092647. Review.

5.

Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.

Merlino F, Billard É, Yousif AM, Di Maro S, Brancaccio D, Abate L, Carotenuto A, Bellavita R, d'Emmanuele di Villa Bianca R, Santicioli P, Marinelli L, Novellino E, Hébert TE, Lubell WD, Chatenet D, Grieco P.

J Med Chem. 2019 Feb 14;62(3):1455-1467. doi: 10.1021/acs.jmedchem.8b01601. Epub 2019 Jan 23.

PMID:
30615452
6.

Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide.

Debbabi S, Groleau MC, Létourneau M, Narayanan C, Gosselin LL, Iddir M, Gagnon J, Doucet N, Déziel E, Chatenet D.

PLoS One. 2018 Nov 21;13(11):e0207366. doi: 10.1371/journal.pone.0207366. eCollection 2018.

7.

Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue.

Billard E, Hébert TE, Chatenet D.

J Med Chem. 2018 Oct 11;61(19):8707-8716. doi: 10.1021/acs.jmedchem.8b00789. Epub 2018 Sep 19.

PMID:
30183282
8.

New insights about the peculiar role of the 28-38 C-terminal segment and some selected residues in PACAP for signaling and neuroprotection.

Poujol de Molliens M, Létourneau M, Devost D, Hébert TE, Fournier A, Chatenet D.

Biochem Pharmacol. 2018 Aug;154:193-202. doi: 10.1016/j.bcp.2018.04.024. Epub 2018 Apr 25.

PMID:
29704474
9.

Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics.

Douchez A, Billard E, Hébert TE, Chatenet D, Lubell WD.

J Med Chem. 2017 Dec 14;60(23):9838-9859. doi: 10.1021/acs.jmedchem.7b01525. Epub 2017 Dec 5.

PMID:
29131958
10.

Insight into the role of urotensin II-related peptide tyrosine residue in UT activation.

Billard E, Létourneau M, Hébert TE, Chatenet D.

Biochem Pharmacol. 2017 Nov 15;144:100-107. doi: 10.1016/j.bcp.2017.08.003. Epub 2017 Aug 4.

PMID:
28784291
11.

Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II.

Strack M, Billard É, Chatenet D, Lubell WD.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3412-3416. doi: 10.1016/j.bmcl.2017.05.088. Epub 2017 May 31.

PMID:
28625362
12.

Understanding GPCR signaling in the brain- the path to CNS drug discovery.

Chatenet D, Hébert TE.

Curr Opin Pharmacol. 2017 Feb;32:v-vii. doi: 10.1016/j.coph.2017.03.001. No abstract available.

PMID:
28417881
13.

Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion.

Tadevosyan A, Xiao J, Surinkaew S, Naud P, Merlen C, Harada M, Qi X, Chatenet D, Fournier A, Allen BG, Nattel S.

J Am Heart Assoc. 2017 Apr 5;6(4). pii: e004965. doi: 10.1161/JAHA.116.004965.

14.

Peptide modification results in the formation of a dimer with a 60-fold enhanced antimicrobial activity.

Thamri A, Létourneau M, Djoboulian A, Chatenet D, Déziel E, Castonguay A, Perreault J.

PLoS One. 2017 Mar 15;12(3):e0173783. doi: 10.1371/journal.pone.0173783. eCollection 2017.

15.

Urotensin II((4-11)) Azasulfuryl Peptides: Synthesis and Biological Activity.

Merlino F, Yousif AM, Billard É, Dufour-Gallant J, Turcotte S, Grieco P, Chatenet D, Lubell WD.

J Med Chem. 2016 May 26;59(10):4740-52. doi: 10.1021/acs.jmedchem.6b00108. Epub 2016 May 17.

PMID:
27140209
16.

Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson's disease.

Lamine-Ajili A, Fahmy AM, Létourneau M, Chatenet D, Labonté P, Vaudry D, Fournier A.

Biochim Biophys Acta. 2016 Apr;1862(4):688-695. doi: 10.1016/j.bbadis.2016.01.005. Epub 2016 Jan 6.

17.

Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.

Vladoiu MC, Labrie M, Létourneau M, Egesborg P, Gagné D, Billard É, Grosset AA, Doucet N, Chatenet D, St-Pierre Y.

Oncotarget. 2015 Dec 1;6(38):40970-80. doi: 10.18632/oncotarget.5403.

18.

Optimization of on-resin palladium-catalyzed Sonogashira cross-coupling reaction for peptides and its use in a structure-activity relationship study of a class B GPCR ligand.

Doan ND, Poujol de Molliens M, Létourneau M, Fournier A, Chatenet D.

Eur J Med Chem. 2015 Nov 2;104:106-14. doi: 10.1016/j.ejmech.2015.09.017. Epub 2015 Sep 21.

PMID:
26448038
19.

Caged ligands to study the role of intracellular GPCRs.

Tadevosyan A, Villeneuve LR, Fournier A, Chatenet D, Nattel S, Allen BG.

Methods. 2016 Jan 1;92:72-7. doi: 10.1016/j.ymeth.2015.07.005. Epub 2015 Jul 18.

PMID:
26196333
20.

Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model.

Lamine A, Létourneau M, Doan ND, Maucotel J, Couvineau A, Vaudry H, Chatenet D, Vaudry D, Fournier A.

Neuropharmacology. 2016 Sep;108:440-50. doi: 10.1016/j.neuropharm.2015.05.014. Epub 2015 May 22.

PMID:
26006268
21.
22.

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function.

Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D.

Pharmacol Rev. 2015;67(1):214-58. doi: 10.1124/pr.114.009480. Review.

PMID:
25535277
23.

Secondary conformational conversion is involved in glycosaminoglycans-mediated cellular uptake of the cationic cell-penetrating peptide PACAP.

Tchoumi Neree A, Nguyen PT, Chatenet D, Fournier A, Bourgault S.

FEBS Lett. 2014 Dec 20;588(24):4590-6. doi: 10.1016/j.febslet.2014.10.029. Epub 2014 Nov 4.

24.

Photoreleasable ligands to study intracrine angiotensin II signalling.

Tadevosyan A, Létourneau M, Folch B, Doucet N, Villeneuve LR, Mamarbachi AM, Pétrin D, Hébert TE, Fournier A, Chatenet D, Allen BG, Nattel S.

J Physiol. 2015 Feb 1;593(3):521-39. doi: 10.1113/jphysiol.2014.279109. Epub 2015 Jan 7.

25.

Design and application of light-activated probes for cellular signaling.

Chatenet D, Bourgault S, Fournier A.

Methods Mol Biol. 2015;1234:17-30. doi: 10.1007/978-1-4939-1755-6_3.

PMID:
25304345
26.

Design of a truncated cardiotoxin-I analogue with potent insulinotropic activity.

Nguyen TT, Folch B, Létourneau M, Truong NH, Doucet N, Fournier A, Chatenet D.

J Med Chem. 2014 Mar 27;57(6):2623-33. doi: 10.1021/jm401904q. Epub 2014 Mar 4.

PMID:
24552570
27.

Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists.

Chatenet D, Folch B, Feytens D, Létourneau M, Tourwé D, Doucet N, Fournier A.

J Med Chem. 2013 Dec 12;56(23):9612-22. doi: 10.1021/jm401153j. Epub 2013 Nov 26.

PMID:
24251366
28.

Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca²⁺ in adult cardiac myocytes.

Merlen C, Farhat N, Luo X, Chatenet D, Tadevosyan A, Villeneuve LR, Gillis MA, Nattel S, Thorin E, Fournier A, Allen BG.

J Mol Cell Cardiol. 2013 Sep;62:189-202. doi: 10.1016/j.yjmcc.2013.05.021. Epub 2013 Jun 10.

29.

Regulation of cardiac nitric oxide signaling by nuclear β-adrenergic and endothelin receptors.

Vaniotis G, Glazkova I, Merlen C, Smith C, Villeneuve LR, Chatenet D, Therien M, Fournier A, Tadevosyan A, Trieu P, Nattel S, Hébert TE, Allen BG.

J Mol Cell Cardiol. 2013 Sep;62:58-68. doi: 10.1016/j.yjmcc.2013.05.003. Epub 2013 May 17.

30.

Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Chatenet D, Nguyen TT, Létourneau M, Fournier A.

Front Endocrinol (Lausanne). 2013 Jan 2;3:174. doi: 10.3389/fendo.2012.00174. eCollection 2012.

31.

Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Chatenet D, Létourneau M, Nguyen QT, Doan ND, Dupuis J, Fournier A.

Br J Pharmacol. 2013 Feb;168(4):807-21. doi: 10.1111/j.1476-5381.2012.02217.x.

32.

Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide.

Doan ND, Létourneau M, Vaudry D, Doucet N, Folch B, Vaudry H, Fournier A, Chatenet D.

J Control Release. 2012 Oct 28;163(2):256-65. doi: 10.1016/j.jconrel.2012.08.021. Epub 2012 Aug 24.

PMID:
22922050
33.

Cardiotoxin-I: an unexpectedly potent insulinotropic agent.

Nguyen TT, Folch B, Létourneau M, Vaudry D, Truong NH, Doucet N, Chatenet D, Fournier A.

Chembiochem. 2012 Aug 13;13(12):1805-12. doi: 10.1002/cbic.201200081. Epub 2012 Jul 16.

PMID:
22807058
34.

Receptor-independent cellular uptake of pituitary adenylate cyclase-activating polypeptide.

Doan ND, Chatenet D, Létourneau M, Vaudry H, Vaudry D, Fournier A.

Biochim Biophys Acta. 2012 Apr;1823(4):940-9. doi: 10.1016/j.bbamcr.2012.02.001. Epub 2012 Feb 9.

35.

Presence of urotensin-II receptors at the cell nucleus: specific tissue distribution and hypoxia-induced modulation.

Nguyen TT, Létourneau M, Chatenet D, Fournier A.

Int J Biochem Cell Biol. 2012 Apr;44(4):639-47. doi: 10.1016/j.biocel.2011.12.022. Epub 2012 Jan 9.

PMID:
22245063
36.

Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers.

Chatenet D, Cescato R, Waser B, Erchegyi J, Rivier JE, Reubi JC.

EJNMMI Res. 2011 Sep 2;1(1):21. doi: 10.1186/2191-219X-1-21.

37.

Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.

Chatenet D, Nguyen QT, Létourneau M, Dupuis J, Fournier A.

Biochem Pharmacol. 2012 Mar 1;83(5):608-15. doi: 10.1016/j.bcp.2011.12.009. Epub 2011 Dec 16.

PMID:
22197588
38.

Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart.

Doan ND, Nguyen TT, Létourneau M, Turcotte K, Fournier A, Chatenet D.

Br J Pharmacol. 2012 May;166(1):243-57. doi: 10.1111/j.1476-5381.2011.01710.x.

39.

Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine.

Fu Y, Létourneau M, Chatenet D, Dupuis J, Fournier A.

Nucl Med Biol. 2011 Aug;38(6):867-74. doi: 10.1016/j.nucmedbio.2011.01.011. Epub 2011 Apr 21.

PMID:
21843783
40.

Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.

Bourgault S, Chatenet D, Wurtz O, Doan ND, Leprince J, Vaudry H, Fournier A, Vaudry D.

Curr Pharm Des. 2011;17(10):1002-24. Review.

PMID:
21524253
41.

Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects.

Doan ND, Bourgault S, Dejda A, Létourneau M, Detheux M, Vaudry D, Vaudry H, Chatenet D, Fournier A.

Biochem Pharmacol. 2011 Feb 15;81(4):552-61. doi: 10.1016/j.bcp.2010.11.015. Epub 2010 Nov 27.

PMID:
21114961
42.

Urotensin II, from fish to human.

Vaudry H, Do Rego JC, Le Mevel JC, Chatenet D, Tostivint H, Fournier A, Tonon MC, Pelletier G, Conlon JM, Leprince J.

Ann N Y Acad Sci. 2010 Jul;1200:53-66. doi: 10.1111/j.1749-6632.2010.05514.x. Review.

PMID:
20633133
43.

The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation.

Jarry M, Diallo M, Lecointre C, Desrues L, Tokay T, Chatenet D, Leprince J, Rossi O, Vaudry H, Tonon MC, Prézeau L, Castel H, Gandolfo P.

Biochem J. 2010 Apr 28;428(1):113-24. doi: 10.1042/BJ20090867.

44.

Characterization of the adrenomedullin receptor acting as the target of a new radiopharmaceutical biomolecule for lung imaging.

Fu Y, Létourneau M, Nguyen QT, Chatenet D, Dupuis J, Fournier A.

Eur J Pharmacol. 2009 Sep 1;617(1-3):118-23. doi: 10.1016/j.ejphar.2009.06.031. Epub 2009 Jun 24.

PMID:
19559019
45.

Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction.

Dubessy C, Cartier D, Lectez B, Bucharles C, Chartrel N, Montero-Hadjadje M, Bizet P, Chatenet D, Tostivint H, Scalbert E, Leprince J, Vaudry H, Jégou S, Lihrmann I.

J Neurochem. 2008 Oct;107(2):361-74. doi: 10.1111/j.1471-4159.2008.05624.x. Epub 2008 Aug 14.

46.

Effect of GABA A receptor activation on UT-coupled signaling pathways in rat cortical astrocytes.

Desrues L, Lefebvre T, Diallo M, Gandolfo P, Leprince J, Chatenet D, Vaudry H, Tonon MC, Castel H.

Peptides. 2008 May;29(5):727-34. doi: 10.1016/j.peptides.2008.01.024. Epub 2008 Feb 15.

PMID:
18355946
47.

Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats.

Chuquet J, Lecrux C, Chatenet D, Leprince J, Chazalviel L, Roussel S, MacKenzie ET, Vaudry H, Touzani O.

Exp Neurol. 2008 Apr;210(2):577-84. doi: 10.1016/j.expneurol.2007.12.004. Epub 2007 Dec 15.

PMID:
18191840
48.

[Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes.

Diallo M, Jarry M, Desrues L, Castel H, Chatenet D, Leprince J, Vaudry H, Tonon MC, Gandolfo P.

Peptides. 2008 May;29(5):813-9. Epub 2007 Nov 6.

PMID:
18082287
49.

Structure-activity relationships of urotensin II and URP.

Leprince J, Chatenet D, Dubessy C, Fournier A, Pfeiffer B, Scalbert E, Renard P, Pacaud P, Oulyadi H, Ségalas-Milazzo I, Guilhaudis L, Davoust D, Tonon MC, Vaudry H.

Peptides. 2008 May;29(5):658-73. Epub 2007 Aug 19. Review.

PMID:
17931747
50.

Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat.

Bruzzone F, Lectez B, Alexandre D, Jégou S, Mounien L, Tollemer H, Chatenet D, Leprince J, Vallarino M, Vaudry H, Chartrel N.

J Comp Neurol. 2007 Aug 1;503(4):573-91.

PMID:
17534937

Supplemental Content

Loading ...
Support Center